GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying
Phase 2
Completed
- Conditions
- Gastroparesis
- Interventions
- Drug: GSK962040 (25 mg tablet)Drug: Placebo
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 58
- Registration Number
- NCT01602549
- Locations
- 🇬🇧
GSK Investigational Site, Norwich, United Kingdom
Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT01602900
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Influenza Burden Assessment in the United States, July1997 - up to April 2009
Completed
- Conditions
- Influenza
- Interventions
- Other: Data collection
- First Posted Date
- 2012-05-16
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01599390
Bupropion & Cardio Birth Defect (Slone)
Completed
- Conditions
- Depressive Disorder
- Interventions
- Drug: Exposure to any bupropion during the first trimesterDrug: Exposure to bupropion alone during the first trimester
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01597661
The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury
Phase 2
Completed
- Conditions
- Lung Injury, Acute
- Interventions
- Drug: Dose 1 GSK2586881Drug: Dose 2 GSK2586881Drug: Placebo (saline)Drug: Dose 3 GSK2586881Drug: Dose 4 GSK2586881
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 44
- Registration Number
- NCT01597635
- Locations
- 🇨🇦
GSK Investigational Site, Sainte-Foy, Quebec, Canada
BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 142
- Registration Number
- NCT01597622
- Locations
- 🇰🇷
GSK Investigational Site, Suwon, Kyonggi-do, Korea, Republic of
Acotral® Versus Zetia® Ezetimibe Bioequivalance Study.
Phase 1
Completed
- Conditions
- Hypercholesterolaemia
- Interventions
- Drug: 10 mg Ezetimibe - wash out period
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 52
- Registration Number
- NCT01597700
- Locations
- 🇮🇳
GSK Investigational Site, Electronics City, Bengalore, India
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus I
- Interventions
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 42
- Registration Number
- NCT01597648
Pertussis Infection in Adolescents and Adults With Prolonged Cough
Not Applicable
Completed
- Conditions
- Pertussis
- Interventions
- Procedure: Blood collectionOther: Data collection
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 337
- Registration Number
- NCT01597687
- Locations
- 🇹🇭
GSK Investigational Site, Songkla, Thailand
A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT01597609
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath